Stefano Volinia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7617235/publications.pdf

Version: 2024-02-01

257 papers

52,856 citations

89 h-index

4345

1410 227

g-index

264 all docs

264 docs citations

times ranked

264

52470 citing authors

#	Article	IF	CITATIONS
1	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, 2022, 107, 1034-1044.	1.7	4
2	Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer. International Journal of Biological Sciences, 2022, 18, 1-14.	2.6	6
3	Targeting the Vav1/miR‑29b axis as a potential approach for treating selected molecular subtypes of triple‑negative breast cancer. Oncology Reports, 2021, 45, .	1.2	4
4	A KRAS-responsive long non-coding RNA controls microRNA processing. Nature Communications, 2021, 12, 2038.	5.8	30
5	Torque teno mini virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion. Blood, 2021, 138, 1773-1777.	0.6	16
6	Inhibition of the IncRNA Coded within Transglutaminase 2 Gene Impacts Several Relevant Networks in MCF-7 Breast Cancer Cells. Non-coding RNA, 2021, 7, 49.	1.3	1
7	The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma. Cancers, 2021, 13, 4355.	1.7	5
8	The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2. Cells, 2021, 10, 3059.	1.8	8
9	UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. Genes, 2021, 12, 1978.	1.0	5
10	The network of non-coding RNAs and their molecular targets in breast cancer. Molecular Cancer, 2020, 19, 61.	7.9	36
11	miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. Progress in Neurobiology, 2020, 190, 101803.	2.8	31
12	Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Advances, 2020, 4, 239-251.	2.5	29
13	miRNAs as Candidate Biomarker for the Accurate Detection of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neoplasia. Frontiers in Oncology, 2019, 9, 526.	1.3	10
14	Involvement of non-coding RNAs and transcription factors in the induction of Transglutaminase isoforms by ATRA. Amino Acids, 2019, 51, 1273-1288.	1.2	7
15	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2019, 18, 1451-1459.	1.9	7
16	MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. International Journal of Radiation Oncology Biology Physics, 2019, 104, 197-206.	0.4	13
17	Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. Leukemia, 2019, 33, 2169-2182.	3.3	52
18	Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers, 2019, 11, 483.	1.7	107

#	Article	IF	Citations
19	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. Journal of Hematology and Oncology, 2019, 12, 114.	6.9	5
20	Ectopic expression of PLCâ€Î²2 in nonâ€invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miRâ€146a. Molecular Carcinogenesis, 2019, 58, 708-721.	1.3	8
21	A long non-coding RNA inside the type 2 transglutaminase gene tightly correlates with the expression of its transcriptional variants. Amino Acids, 2018, 50, 421-438.	1.2	7
22	Loss of miR-204 expression is a key event in melanoma. Molecular Cancer, 2018, 17, 71.	7.9	25
23	SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?. High-Throughput, 2018, 7, 34.	4.4	48
24	Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts. Biomarker Research, 2018, 6, 31.	2.8	17
25	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Molecular Therapy - Nucleic Acids, 2018, 13, 334-346.	2.3	43
26	The Network of Non-coding RNAs in Cancer Drug Resistance. Frontiers in Oncology, 2018, 8, 327.	1.3	96
27	Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Frontiers in Genetics, 2018, 9, 174.	1.1	46
28	Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget, 2018, 9, 4354-4365.	0.8	16
29	Levels of miR-126 and miR-218 are elevated in ductal carcinoma <i>in situ</i> (DCIS) and inhibit malignant potential of DCIS derived cells. Oncotarget, 2018, 9, 23543-23553.	0.8	12
30	Abstract 2455: The long non-coding RNA (lncRNA) <i>DANCR</i> in acute myeloid leukemia (AML) stem cells (LSC). Cancer Research, 2018, 78, 2455-2455.	0.4	1
31	Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. Journal of Immunology, 2017, 198, 2500-2512.	0.4	43
32	Blood to skin recirculation of CD4 + memory T cells associates with cutaneous and systemic manifestations of psoriatic disease. Clinical Immunology, 2017, 180, 84-94.	1.4	26
33	miRâ \in 130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology. Cancer Cytopathology, 2017, 125, 635-643.	1.4	18
34	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica, 2017, 102, 1391-1400.	1.7	28
35	Elucidating the role of the long non-coding RNA dancr in leukemic stem cells in acute myeloid leukemia (AML). Experimental Hematology, 2017, 53, S124.	0.2	0
36	Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Research, 2017, 77, 207-218.	0.4	23

#	Article	IF	Citations
37	Variants in microRNA genes in familial papillary thyroid carcinoma. Oncotarget, 2017, 8, 6475-6482.	0.8	8
38	The ubiquitous â€~cancer mutational signature' 5 occurs specifically in cancers with deleted <i>FHIT</i> alleles. Oncotarget, 2017, 8, 102199-102211.	0.8	17
39	Abstract 3856: Identification of circulating tumour cells in breast cancer patient-derived xenograft models., 2017,,.		O
40	Profiling of the Predicted Circular RNAs in Ductal In Situ and Invasive Breast Cancer: A Pilot Study. International Journal of Genomics, 2016, 2016, 1-7.	0.8	30
41	Deregulated microRNAs in breast ductal carcinoma in situ (DCIS) with invasive propensity. European Journal of Cancer, 2016, 61, S32.	1.3	0
42	A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks Journal of Biological Chemistry, 2016, 291, 14914.	1.6	1
43	Genetic variants in thyroid cancer distant metastases. Endocrine-Related Cancer, 2016, 23, L33-L36.	1.6	9
44	WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma. Cancer Research, 2016, 76, 6107-6117.	0.4	38
45	Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with $t(11;19)(q23;p13.1)$ and $t(11;19)(q23;p13.3)$. Leukemia, 2016, 30, 1586-1589.	3.3	10
46	HOXB-AS3 Regulates Cell Cycle Progression and Interacts with the Drosophila Splicing Human Behavior (DSHB) Complex in NPM1-Mutated Acute Myeloid Leukemia. Blood, 2016, 128, 1514-1514.	0.6	4
47	Abstract 4501: Immunophenotypic identities of clinical samples have the potential to correlate with overall survival in cytogenetically normal AML patients. , 2016, , .		0
48	The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model. BMC Medical Genetics, 2015, 16, 46.	2.1	13
49	Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia, 2015, 29, 567-575.	3.3	69
50	miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. Oncotarget, 2015, 6, 4920-4935.	0.8	58
51	Quaking and <i>miR-155</i> ii>interactions in inflammation and leukemogenesis. Oncotarget, 2015, 6, 24599-24610.	0.8	37
52	Abstract P1-07-02: Mesenchymal stem cell regulated microRNAs converge on the speech gene FOXP2 and regulate breast cancer metastasis., 2015,,.		0
53	Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development. Blood, 2015, 126, 1791-1791.	0.6	0
54	MicroRNA Profiles Discriminate among Colon Cancer Metastasis. PLoS ONE, 2014, 9, e96670.	1.1	99

#	Article	IF	Citations
55	A MiRNA Signature for Defining Aggressive Phenotype and Prognosis in Gliomas. PLoS ONE, 2014, 9, e108950.	1.1	60
56	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, 2014, 5, 7162-7171.	0.8	35
57	A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. Genome Medicine, 2014, 6, 76.	3.6	32
58	Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene, 2014, 33, 5319-5331.	2.6	67
59	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18679-18684.	3.3	214
60	Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	37
61	Differential expression of microRNA501â€5p affects the aggressiveness of clear cell renal carcinoma. FEBS Open Bio, 2014, 4, 952-965.	1.0	16
62	Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene, 2014, 33, 702-712.	2.6	65
63	Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis. BMC Cancer, 2014, 14, 84.	1.1	36
64	Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score. Journal of Clinical Oncology, 2014, 32, 548-556.	0.8	134
65	MSC-Regulated MicroRNAs Converge on the Transcription Factor FOXP2 and Promote Breast Cancer Metastasis. Cell Stem Cell, 2014, 15, 762-774.	5.2	155
66	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia, 2014, 28, 1754-1758.	3.3	24
67	Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. Cancer Research, 2014, 74, 1429-1439.	0.4	59
68	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia, 2014, 28, 1252-1258.	3.3	45
69	Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood, 2014, 123, 2412-2415.	0.6	43
70	Abstract 1475: Plasma circulating miRNAs: a new potential biomarker for prostate cancer diagnosis. , 2014, , .		1
71	Abstract 1479: A miRNA signature distinguishing low-grade and high-grade gliomas shows miR-21 and 210 as promising biomarkers of aggressive phenotype and prognosis. , 2014, , .		1
72	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. Journal of Clinical Investigation, 2014, 124, 1512-1524.	3.9	52

#	Article	IF	Citations
73	Abstract 540: Characterization of miR-9 expression and activation in canine osteosarcoma., 2014,,.		O
74	Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Molecular Cancer, 2013, 12, 13.	7.9	63
75	Next generation analysis of breast cancer genomes for precision medicine. Cancer Letters, 2013, 339, 1-7.	3.2	19
76	MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma. Clinical Cancer Research, 2013, 19, 5423-5433.	3.2	98
77	B-cell malignancies in microRNA $\widehat{E1}$ /4-miR-17 \widehat{a} 1/492 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18208-18213.	3.3	69
78	A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9845-9850.	3.3	176
79	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	4.2	121
80	Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15043-15048.	3.3	143
81	MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia. Clinical and Translational Gastroenterology, 2013, 4, e34.	1.3	32
82	A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia, 2013, 27, 2023-2031.	3.3	50
83	Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RAR \hat{I}^2 and tumor regression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9812-9817.	3.3	53
84	Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7413-7417.	3.3	149
85	Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: <i>miR-155</i> Upregulation Independently Identifies High-Risk Patients. Journal of Clinical Oncology, 2013, 31, 2086-2093.	0.8	165
86	inv(16)/t(16;16) acute myeloid leukemia with non–type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood, 2013, 121, 385-391.	0.6	39
87	Association between idiopathic hearing loss and mitochondrial DNA mutations: A study on 169 hearing-impaired subjects. International Journal of Molecular Medicine, 2013, 32, 785-794.	1.8	16
88	Comparison of MicroRNA Deep Sequencing of Matched Formalin-Fixed Paraffin-Embedded and Fresh Frozen Cancer Tissues. PLoS ONE, 2013, 8, e64393.	1.1	62
89	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. Journal of Clinical Investigation, 2013, 123, 4144-4157.	3.9	192
90	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Cell Biology, 2013, 201, i4-i4.	2.3	0

#	Article	IF	Citations
91	Abstract LB-251: Comparison of MicroRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues , 2013, , .		O
92	Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2013, 122, 2540-2540.	0.6	0
93	Multivariate Analysis Reveals a miRNA Profile Correlated To Karyotype and Outcome In Pediatric B-Cell Precursor ALL. Blood, 2013, 122, 2597-2597.	0.6	0
94	MicroRNA Expression Signatures in Solid Malignancies. Cancer Journal (Sudbury, Mass), 2012, 18, 238-243.	1.0	72
95	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology, 2012, 25, 1333-1344.	2.9	48
96	Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3024-3029.	3.3	334
97	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the EÂμ-miR-155 transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20047-20052.	3.3	121
98	Unexpected findings of variability in microRNAs suggest roles in human genetics. Genome Medicine, 2012, 4, 69.	3.6	1
99	The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood, 2012, 120, 2631-2638.	0.6	97
100	The miR- $17\hat{a}^{-1}/492$ family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia, 2012, 26, 1584-1593.	3.3	77
101	miRNA Signatures Associate with Pathogenesis and Progression of Osteosarcoma. Cancer Research, 2012, 72, 1865-1877.	0.4	341
102	Prion proteins (PRNP and PRND) are overâ€expressed in osteosarcoma. Journal of Orthopaedic Research, 2012, 30, 1004-1012.	1.2	15
103	The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). Blood, 2012, 120, 1387-1387.	0.6	1
104	SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML). Blood, 2012, 120, 773-773.	0.6	1
105	Abstract 5032: New insights of miR-221 and miR-222 cluster functions in Burkitt lymphoma, 2012, , .		0
106	Abstract 184: Breed-associated differential microRNA expression in canine osteosarcoma., 2012,,.		0
107	Abstract 2947: B-cell lymphoma in eα-miR-17â^1/492 transgenic mice. , 2012, , .		0
108	MiR-221 and MiR-222 Patterns Characterize Burkitt Lymphoma in Human and Mouse Model. Blood, 2012, 120, 1304-1304.	0.6	0

#	Article	IF	CITATIONS
109	Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance). Blood, 2012, 120, 1293-1293.	0.6	O
110	The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia, 2011, 25, 1869-1876.	3.3	110
111	p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. Journal of Experimental Medicine, 2011, 208, 875-883.	4.2	480
112	Mutator activity induced by microRNA-155 ($<$ i> $>$ miR-155 $<$ /i> $>$) links inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4908-4913.	3.3	226
113	OMiR: Identification of associations between OMIM diseases and microRNAs. Genomics, 2011, 97, 71-76.	1.3	14
114	miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood, 2011, 118, 3072-3079.	0.6	115
115	Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. British Journal of Haematology, 2011, 153, 24-32.	1.2	70
116	Onconase mediated NFK \hat{l}^2 downregulation in malignant pleural mesothelioma. Oncogene, 2011, 30, 2767-2777.	2.6	52
117	Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer, 2011, 117, 4696-4706.	2.0	55
118	MicroRNA expression profiling in human Barrett's carcinogenesis. International Journal of Cancer, 2011, 129, 1661-1670.	2.3	100
119	GAMES identifies and annotates mutations in next-generation sequencing projects. Bioinformatics, 2011, 27, 9-13.	1.8	28
120	Down-regulation of homeobox genes <i>MEIS1</i> and <i>HOXA</i> in <i>MLL</i> -rearranged acute leukemia impairs engraftment and reduces proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7956-7961.	3.3	56
121	miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. British Journal of Cancer, 2011, 105, 1023-1029.	2.9	67
122	Common Fragile Site Tumor Suppressor Genes and Corresponding Mouse Models of Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-10.	3.0	19
123	Abstract LB-109: BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment., $2011,$		2
124	Abstract 156: MicroRNA expression profiling of human esophageal metaplastic changes., 2011,,.		0
125	Abstract 1143: Deep sequencing of microRNAs in canine diffuse large B-cell lymphoma. , 2011, , .		0
126	Abstract LB-347: A microRNA signature harbors prognostic implications in clear cell renal carcinoma (ccRC)., 2011,,.		0

#	Article	IF	Citations
127	p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. Journal of Cell Biology, 2011, 193, i8-i8.	2.3	О
128	MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene. Blood, 2011, 118, 2846-2846.	0.6	0
129	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952.	0.6	200
130	Reprogramming of miRNA networks in cancer and leukemia. Genome Research, 2010, 20, 589-599.	2.4	331
131	Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of $TGF\hat{l}^2$ signaling pathway in SW480 cells. Biochemical Pharmacology, 2010, 80, 2057-2065.	2.0	221
132	Selected MicroRNAs Define Cell Fate Determination of Murine Central Memory CD8 T Cells. PLoS ONE, 2010, 5, e11243.	1.1	52
133	Epigenetically Deregulated microRNA-375 Is Involved in a Positive Feedback Loop with Estrogen Receptor α in Breast Cancer Cells. Cancer Research, 2010, 70, 9175-9184.	0.4	260
134	Strong Inverse Correlation Between MicroRNA-125b and Human Papillomavirus DNA in Productive Infection. Diagnostic Molecular Pathology, 2010, 19, 135-143.	2.1	56
135	GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGFβ effectors, Drosha and microRNAs with opposite oncogenic potentials. Nucleic Acids Research, 2010, 38, 7673-7688.	6.5	32
136	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	3.3	306
137	MicroRNA Cluster 221-222 and Estrogen Receptor \hat{l}_{\pm} Interactions in Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 706-721.	3.0	301
138	Identification of microRNA activity by Targets' Reverse EXpression. Bioinformatics, 2010, 26, 91-97.	1.8	39
139	Fhit loss in lung preneoplasia: Relation to DNA damage response checkpoint activation. Cancer Letters, 2010, 291, 230-236.	3.2	8
140	Chronic lymphocytic leukemia modeled in mouse by targeted <i>miR-29</i> expression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12210-12215.	3.3	167
141	Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncology, The, 2010, 11, 136-146.	5.1	752
142	miR-221 overexpression contributes to liver tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 264-269.	3.3	679
143	Non-coding RNAs: a key to future personalized molecular therapy?. Genome Medicine, 2010, 2, 12.	3.6	97
144	Abstract 3050: MicroRNA expression profiling of human Barrett's carcinogenesis. Cancer Research, 2010, 70, 3050-3050.	0.4	3

#	Article	IF	CITATIONS
145	BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment. Blood, 2010, 116, 515-515.	0.6	14
146	Abstract 3011: MicroRNA expression profiles in benign and aggressive canine mast cell tumors. , 2010, , .		O
147	Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling Networks. Journal of Biological Chemistry, 2009, 284, 27487-27499.	1.6	121
148	MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 2009, 113, 6411-6418.	0.6	729
149	Altered expression of selected microRNAs in melanoma: Antiproliferative and proapoptotic activity of miRNA-155. International Journal of Oncology, 2009, , .	1.4	30
150	Targeted Ablation of the WW Domain-Containing Oxidoreductase Tumor Suppressor Leads to Impaired Steroidogenesis. Endocrinology, 2009, 150, 1530-1535.	1.4	94
151	UCbase & miRfunc: a database of ultraconserved sequences and microRNA function. Nucleic Acids Research, 2009, 37, D41-D48.	6.5	38
152	Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology, 2009, 50, 1152-1161.	3.6	274
153	Fragile histidine triad protein, WW domainâ€containing oxidoreductase protein Wwox, and activator protein 2γ expression levels correlate with basal phenotype in breast cancer. Cancer, 2009, 115, 899-908.	2.0	41
154	MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. Journal of Pathology, 2009, 219, 214-221.	2.1	449
155	A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nature Protocols, 2009, 4, 107-115.	5.5	122
156	Induced Pluripotent Stem Cells and Embryonic Stem Cells Are Distinguished by Gene Expression Signatures. Cell Stem Cell, 2009, 5, 111-123.	5.2	915
157	Zinc Replenishment Reverses Overexpression of the Proinflammatory Mediator S100A8 and Esophageal Preneoplasia in the Rat. Gastroenterology, 2009, 136, 953-966.	0.6	44
158	MicroRNA expression profiling of male breast cancer. Breast Cancer Research, 2009, 11, R58.	2,2	103
159	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood, 2009, 113, 5568-5574.	0.6	129
160	MicroRNA 29b functions in acute myeloid leukemia. Blood, 2009, 114, 5331-5341.	0.6	412
161	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood, 2009, 114, 3872-3879.	0.6	179
162	Significance of Aberrant Expression of MicroRNAs in Cancer Cells. , 2009, , 1-12.		0

#	Article	IF	CITATIONS
163	Cytogenetic and array CGH characterization of an intrachromosomal complex rearrangement of 4q in a patient with a 4qâ€phenotype. American Journal of Medical Genetics, Part A, 2008, 146A, 110-115.	0.7	13
164	MicroRNA expression profiling using microarrays. Nature Protocols, 2008, 3, 563-578.	5.5	264
165	E2F1-Regulated MicroRNAs Impair TGFÎ ² -Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell, 2008, 13, 272-286.	7.7	818
166	A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13906-13911.	3.3	503
167	MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5166-5171.	3.3	741
168	Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer. Cancer Research, 2008, 68, 6162-6170.	0.4	661
169	The WWOX Tumor Suppressor Is Essential for Postnatal Survival and Normal Bone Metabolism. Journal of Biological Chemistry, 2008, 283, 21629-21639.	1.6	132
170	MicroRNA Microarray Identifies <i>Let-7i</i> as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer. Cancer Research, 2008, 68, 10307-10314.	0.4	343
171	MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12885-12890.	3.3	507
172	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3945-3950.	3.3	471
173	Epstein-Barr Virus-Induced miR-155 Attenuates NF-κB Signaling and Stabilizes Latent Virus Persistence. Journal of Virology, 2008, 82, 10436-10443.	1.5	207
174	TOM: enhancement and extension of a tool suite for in silico approaches to multigenic hereditary disorders. Bioinformatics, 2008, 24, 428-429.	1.8	18
175	Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7004-7009.	3.3	491
176	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 2008, 111, 3183-3189.	0.6	575
177	Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood, 2008, 111, 816-828.	0.6	44
178	Genome Wide Identification of Recessive Cancer Genes by Combinatorial Mutation Analysis. PLoS ONE, 2008, 3, e3380.	1.1	12
179	Fun&Co: identification of key functional differences in transcriptomes. Bioinformatics, 2007, 23, 2725-2732.	1.8	2
180	MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis. JAMA - Journal of the American Medical Association, 2007, 297, 1901.	3.8	1,046

#	Article	IF	CITATIONS
181	Wwox Suppresses Prostate Cancer Cell Growth through Modulation of ErbB2-Mediated Androgen Receptor Signaling. Molecular Cancer Research, 2007, 5, 957-965.	1.5	26
182	MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene, 2007, 26, 4148-4157.	2.6	351
183	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15805-15810.	3.3	1,538
184	MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, 2007, 67, 8699-8707.	0.4	1,356
185	Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma. Translational Research, 2007, 150, 233-245.	2.2	25
186	Compatible solutes from hyperthermophiles improve the quality of DNA microarrays. BMC Biotechnology, 2007, 7, 82.	1.7	14
187	Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene, 2007, 26, 7590-7595.	2.6	373
188	Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature, 2007, 449, 919-922.	13.7	827
189	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	7.7	681
190	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2257-2261.	3.3	5,220
191	Microarray and Large-ScaleIn Silico–Based Identification of Genes Functionally Related to Haptoglobin and/or Hemopexin. DNA and Cell Biology, 2006, 25, 323-330.	0.9	9
192	Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by miR-29 and miR-181. Cancer Research, 2006, 66, 11590-11593.	0.4	568
193	Gene Expression Analysis in HBV Transgenic Mouse Liver: A Model to Study Early Events Related to Hepatocarcinogenesis. Molecular Medicine, 2006, 12, 115-123.	1.9	31
194	Skin homing of Seleary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood, 2006, 107, 1108-1115.	0.6	148
195	Evidence of genetic underexpression in chorionic villi samples of euploid fetuses with increased nuchal translucency at 10–11 weeks' gestation. Prenatal Diagnosis, 2006, 26, 128-133.	1.1	15
196	Cord blood in vitro expanded CD41+ cells: identification of novel components of megakaryocytopoiesis. Journal of Thrombosis and Haemostasis, 2006, 4, 848-860.	1.9	23
197	Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene, 2006, 25, 2860-2872.	2.6	62
198	Finding biological process modifications in cancer tissues by mining gene expression correlations. BMC Bioinformatics, 2006, 7, 6.	1.2	13

#	Article	IF	CITATIONS
199	MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior. Journal of Clinical Oncology, 2006, 24, 4677-4684.	0.8	752
200	TOM: a web-based integrated approach for identification of candidate disease genes. Nucleic Acids Research, 2006, 34, W285-W292.	6.5	55
201	MicroRNA fingerprints during human megakaryocytopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5078-5083.	3.3	403
202	A Role for the WWOX Gene in Prostate Cancer. Cancer Research, 2006, 66, 6477-6481.	0.4	92
203	Effect of Rapamycin on Mouse Chronic Lymphocytic Leukemia and the Development of Nonhematopoietic Malignancies in El¼-TCL1 Transgenic Mice. Cancer Research, 2006, 66, 915-920.	0.4	69
204	Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in EÂ-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7024-7029.	3.3	1,023
205	P253R fibroblast growth factor receptor-2 mutation induces RUNX2 transcript variants and calvarial osteoblast differentiation. Journal of Cellular Physiology, 2005, 202, 524-535.	2.0	39
206	Akt, protein kinase C, and mitogen-activated protein kinase phosphorylation status in head and neck squamous cell carcinoma. Head and Neck, 2005, 27, 130-137.	0.9	13
207	miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13944-13949.	3.3	3,287
208	The role of microRNA genes in papillary thyroid carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 19075-19080.	3.3	1,137
209	MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 2005, 65, 7065-7070.	0.4	3,719
210	A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2005, 353, 1793-1801.	13.9	2,255
211	Bayesian Networks Learning for Gene Expression Datasets. Lecture Notes in Computer Science, 2005, , 109-120.	1.0	3
212	Analysis of MG63 osteoblastic-cell response to a new nanoporous implant surface by means of a microarray technology. Clinical Oral Implants Research, 2004, 15, 180-186.	1.9	48
213	Zirconium oxide: analysis of MG63 osteoblast-like cell response by means of a microarray technology. Biomaterials, 2004, 25, 215-228.	5.7	89
214	P-15 Cell-Binding Domain Derived from Collagen: Analysis of MG63 Osteoblastic-Cell Response by Means of a Microarray Technology. Journal of Periodontology, 2004, 75, 66-83.	1.7	20
215	An expression atlas of connexin genes in the mouse. Genomics, 2004, 83, 812-820.	1.3	29
216	RNA expression induced by cisplatin in an organ of Corti-derived immortalized cell line. Hearing Research, 2004, 196, 8-18.	0.9	25

#	Article	IF	Citations
217	GOAL: automated Gene Ontology analysis of expression profiles. Nucleic Acids Research, 2004, 32, W492-W499.	6.5	40
218	Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood, 2004, 103, 4317-4321.	0.6	167
219	Genetic portrait of malignant granular cell odontogenic tumour. Oral Oncology, 2003, 39, 69-77.	0.8	24
220	Titanium-cell interaction: Analysis of gene expression profiling. Journal of Biomedical Materials Research Part B, 2003, 66B, 341-346.	3.0	60
221	Nuclear phosphoinositide 3-kinase $C2\hat{l}^2$ activation during $G2/M$ phase of the cell cycle in HL-60 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 61-71.	1.2	34
222	Genetic Profile of Clear Cell Odontogenic Carcinoma. Journal of Craniofacial Surgery, 2003, 14, 356-362.	0.3	22
223	Hepatocyte growth factor activates phosphoinositide 3-kinase $C2\hat{l}^2$ in renal brush-border plasma membranes. Biochemical Journal, 2002, 365, 791-799.	1.7	15
224	The activation of nuclear phosphoinositide 3-kinase $C2\hat{l}^2$ in all-trans-retinoic acid-differentiated HL-60 cells. FEBS Letters, 2002, 529, 268-274.	1.3	36
225	Expression Profiles of Craniosynostosis-Derived Fibroblasts. Molecular Medicine, 2002, 8, 638-644.	1.9	25
226	The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature, 2002, 419, 853-857.	13.7	390
227	Expression profiles of craniosynostosis-derived fibroblasts. Molecular Medicine, 2002, 8, 638-44.	1.9	12
228	Identification of differentially expressed genes in human salivary gland tumors by DNA microarrays. Molecular Cancer Therapeutics, 2002, 1, 533-8.	1.9	37
229	A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nature Biotechnology, 2001, 19, 348-353.	9.4	509
230	Presence and Activation of Nuclear Phosphoinositide 3-Kinase C2β during Compensatory Liver Growth. Journal of Biological Chemistry, 2001, 276, 17754-17761.	1.6	42
231	Supra-Agonist Peptides Enhance the Reactivation of Memory CTL Responses. Journal of Immunology, 2000, 165, 4264-4271.	0.4	21
232	Structural Analysis of 14-3-3 Phosphopeptide Complexes Identifies a Dual Role for the Nuclear Export Signal of 14-3-3 in Ligand Binding. Molecular Cell, 1999, 4, 153-166.	4.5	467
233	Nuclear association of tyrosine-phosphorylated Vav to phospholipase $C-\hat{l}^31$ and phosphoinositide 3-kinase during granulocytic differentiation of HL-60 cells. FEBS Letters, 1998, 441, 480-484.	1.3	48
234	Human Phosphoinositide 3-Kinase $C2\hat{l}^2$, the Role of Calcium and the C2 Domain in Enzyme Activity. Journal of Biological Chemistry, 1998, 273, 33082-33090.	1.6	116

#	Article	IF	CITATIONS
235	A Type II Phosphoinositide 3-Kinase Is Stimulated via Activated Integrin in Platelets. Journal of Biological Chemistry, 1998, 273, 14081-14084.	1.6	97
236	Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochemical Journal, 1997, 326, 139-147.	1.7	228
237	p $110 \hat{A}$, a novel phosphoinositide 3-kinase in leukocytes. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 4330-4335.	3.3	403
238	The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity. Cell, 1997, 91, 961-971.	13.5	1,509
239	The translocation $t(8;16)(p11;p13)$ of acute myeloid leukaemia fuses a putative acetyltransferase to the CREBâ \in "binding protein. Nature Genetics, 1996, 14, 33-41.	9.4	740
240	Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science, 1995, 269, 690-693.	6.0	687
241	Identification of a set of frequent decanucleotides in plants and in animals. Bioinformatics, 1994, 10, 465-470.	1.8	1
242	A set of Alu-free frequent decamers from mammalian genomes enriched in transcription factor signals. Bioinformatics, 1994, 10, 501-508.	1.8	2
243	Characterization of a phosphatidylinositol-specific phosphoinositide 3-kinase from mammalian cells. Current Biology, 1994, 4, 203-214.	1.8	138
244	Molecular Cloning, cDNA Sequence, and Chromosomal Localization of the Human Phosphatidylinositol 3-Kinase p110l± (PIK3CA) Gene. Genomics, 1994, 24, 472-477.	1.3	107
245	Phosphatidylinositol 3-kinase: Structure and expression of the 110 kd catalytic subunit. Cell, 1992, 70, 419-429.	13.5	698
246	Microevolution in Ferrara: Isonymy 1890–1990. Annals of Human Biology, 1992, 19, 371-385.	0.4	33
247	Molecular Evolution of the Ha-ras-1 Oncogene: Relationship between DNA Methylation, Frequency of CpG Dinucleotides and Binding to the Sp1 Transacting Factor., 1991,, 163-172.		1
248	Physical maps of 4p16.3, the area expected to contain the Huntington disease mutation. Genomics, 1990, 6, 1-15.	1.3	87
249	Human HLA-DRα gene: a rare oligonucleotide (GTATA) identifies an upstream sequence required for nuclear protein binding. FEBS Letters, 1990, 268, 51-54.	1.3	14
250	The frequency of oligonucleotides in mammalian genic regions. Bioinformatics, 1989, 5, 33-40.	1.8	9
251	A frequent factor XII gene mutation in Hageman trait. Human Genetics, 1988, 80, 149-151.	1.8	8
252	CG Dinucleotides of class II MHC genes are mutation hot-spots. Cytotechnology, 1988, 1, 133-138.	0.7	2

STEFANO VOLINIA

#	Article	IF	CITATIONS
253	A HindIII RFLP and a gene lesion in the coagulation factor VIII gene. Human Genetics, 1988, 78, 359-362.	1.8	22
254	Co-localization of rare oligonucleotides and regulatory elements in mammalian upstream gene regions. Journal of Molecular Biology, 1988, 203, 385-390.	2.0	18
255	Construction of aNotl linking library and isolation of new markers close to the Huntington's disease gene. Nucleic Acids Research, 1988, 16, 9185-9198.	6.5	77
256	Clustering of undermethylated CCGG and GCGC sequences in the $5\hat{a} \in \mathbb{C}^2$ region of the Ha-ras-1 oncogene of human leukemic K562 cells. Biochemical and Biophysical Research Communications, 1987, 145, 96-104.	1.0	11
257	RFLP analysis in families with sporadic hemophilia A. Human Genetics, 1987, 76, 253-6.	1.8	19